Zimmer Biomet Holdings, Inc. (NYSE:ZBH) had its price objective hoisted by Morgan Stanley from $137.00 to $150.00 in a research report released on Monday, July 17th. Morgan Stanley currently has an overweight rating on the medical equipment provider’s stock.
A number of other research analysts also recently weighed in on ZBH. Canaccord Genuity reaffirmed a buy rating and set a $141.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Stifel Nicolaus reaffirmed a hold rating and set a $125.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Guggenheim raised Zimmer Biomet Holdings from a neutral rating to a buy rating and set a $157.00 price target on the stock in a research note on Wednesday, July 12th. Needham & Company LLC reaffirmed a strong-buy rating and set a $153.00 price target on shares of Zimmer Biomet Holdings in a research note on Wednesday, July 12th. Finally, Royal Bank Of Canada reaffirmed an outperform rating and set a $140.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Zimmer Biomet Holdings presently has an average rating of Hold and an average target price of $137.76.
Zimmer Biomet Holdings (NYSE ZBH) opened at 117.19 on Monday. The company’s 50 day moving average price is $127.65 and its 200-day moving average price is $121.39. The company has a market capitalization of $23.65 billion, a P/E ratio of 33.38 and a beta of 1.20. Zimmer Biomet Holdings has a 12-month low of $95.63 and a 12-month high of $133.49.
Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing analysts’ consensus estimates of $2.10 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The firm had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.95 billion. During the same period last year, the company posted $2.02 earnings per share. The firm’s quarterly revenue was up 1.1% compared to the same quarter last year. Equities analysts forecast that Zimmer Biomet Holdings will post $8.24 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Zimmer Biomet Holdings, Inc. (NYSE:ZBH) PT Raised to $150.00” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://stocknewstimes.com/2017/08/08/zimmer-biomet-holdings-inc-nysezbh-pt-raised-to-150-00-at-morgan-stanley-updated-updated.html.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 22nd will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.82%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is 27.59%.
In other news, VP Tony W. Collins sold 16,986 shares of the firm’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sang Yi sold 17,731 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of ZBH. Parkside Financial Bank & Trust raised its position in Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 22 shares during the last quarter. Parallel Advisors LLC raised its position in Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock worth $138,000 after buying an additional 199 shares during the last quarter. IHT Wealth Management LLC raised its position in Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock worth $139,000 after buying an additional 256 shares during the last quarter. Sandy Spring Bank raised its position in Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock worth $149,000 after buying an additional 20 shares during the last quarter. Finally, Penserra Capital Management LLC raised its position in Zimmer Biomet Holdings by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,288 shares of the medical equipment provider’s stock worth $157,000 after buying an additional 112 shares during the last quarter. 83.62% of the stock is owned by hedge funds and other institutional investors.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
